AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2024
Jan 11, 2024
65314_rns_2024-01-11_3a56b95b-3bab-4a19-b5b7-65ff9710004f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX Release 12 January 2024
==> picture [152 x 42] intentionally omitted <==
ASX Code: MEM
Entitlement Offer Prospectus Shortfall
Pursuant to the pro-rata non-renounceable Entitlement Offer Prospectus dated 4 December 2023 and lodged with ASIC and ASX on same day, the Entitlement Offer closed on 9 January 2024.
A total of 213,227,774 rights to shares were offered under the Entitlement Offer and as at the closing date, 54,305,732 rights to shares were accepted.
The shortfall of 158,922,042 rights to shares are to be placed by the underwriter to the offer, Canaccord Genuity (Australia) Limited.
For further information please contact:
ENDS
For further information, please contact:
Dr David Ali David Tasker Interim Managing Director / Chief Executive Officer Managing Director Memphasys Limited Chapter One Advisors Tel: +61 2 8415 7300 Tel: +61 433 112 936 E: [email protected]> E: [email protected]
About Memphasys
Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.
Website : www.memphasys.com
The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.